Syntex' low dose Tri-Norinyl
Executive Summary
Triphasic oral contraceptive product has been approved by FDA, firm said April 13. Maintaining that the product is "the lowest dose (overall hormonal content) multiphasic regimen" in the U.S., Syntex said that by varying the hormone content through the reproductive cycle unwanted side-effects such as breakthrough bleeding and spotting are reduced. Tri-Norinyl is available in either 21 or 28 day regimens. Price to whslrs. will be the same as for Brevicon and Norinyl, the firm's other low dose oral contraceptive products.